Tango cuts 14% of staff, delays readouts, plans 2027 pancreatic Phase 3

Tango is a clinical-stage company: it has no approved products, no product sales, and it may never turn a profit.¹ Its two lead drugs, vopimetostat (also called TNG462) and TNG456, block an enzyme called PRMT5 in tumors that have lost a gene called MTAP. That gene loss shows up in 10% to 15% of cancers.² Pancreatic cancer is the main target: Tango counts about 24,000 of the roughly 60,000 American pancreatic cancer patients each year as having the MTAP loss. Bristol Myers Squibb, Amgen, AstraZeneca, BeOne and Abbisko are testing similar drugs in early trials.³

The pancreatic plan leans on a partner. Revolution Medicines makes daraxonrasib and zoldonrasib, drugs that block the active form of a protein called RAS.¹ Under a supply deal it provides them free for trials that include vopimetostat, while Tango runs those trials and pays their costs. Tango calls the deal a related-party transaction because the two companies share ties among managers and board members.² Daraxonrasib itself is already approved, as a patient-group leader quoted in Tango's release noted.³

The first combination data, in June 2026, showed tumors shrinking in 11 of 12 pancreatic patients, a 92% response rate.¹ The stock jumped as much as 48% that day, Bloomberg reported.² Tango then sold 21,166,676 shares at $30.00 each plus pre-funded warrants for 1,833,395 more shares, raising $690.0 million and keeping $651.4 million after $38.6 million of costs.³ For contrast, the stock had closed at $8.90 on November 20, 2025. In May 2026 Tango also dropped another drug, TNG260, for limited benefit to patients.⁴

On August 11, 2026 Tango reported a second-quarter net loss of $55.3 million and no revenue. Research spending was $37.2 million and overhead was $22.6 million.¹ It promised lung cancer data for vopimetostat alone and first TNG456 data in the second half of 2026. It also hired a chief commercialization officer and set up a program to sell up to $400 million of new stock straight into the market.²

The board approved the plan on October 22, 2026. It keeps Tango focused on its two PRMT5 drugs and deprioritizes the hunt for new drug targets.¹ Tango will cut about 14% of its workforce, and most of the job losses come from the research group.² At the end of 2025 Tango had 137 full-time employees, 97 of them in research and development. If the staff were the same size today, 14% would be about 19 people, but Tango has hired since, including its new commercial chief.³

Tango gives no charge or yearly savings for the cut, so older yardsticks have to do. In 2025 it spent $10.2 million directly on discovery work, down from $24.4 million the year before, and research staff cost $51.5 million.¹ In the second quarter of 2026, research spending was $37.2 million: $12.3 million went straight to vopimetostat and $2.5 million to TNG456, leaving $22.4 million not charged to either drug.² Against a six-month net loss of $100.9 million, any saving here looks modest. The cut reads as a trim that moves money toward late-stage trials, not a lifeline.³

The cut came with a slower clock. On August 11, 2026 Tango promised lung cancer data for vopimetostat alone and first TNG456 data in the second half of 2026.¹ Both are now due in January 2027, just past that window, and the filing gives no reason. The slip moves two catalysts out of 2026 and stacks them in the same month.²

The pancreatic data are the main event. At the August 20, 2026 cutoff, 22 patients who had already had one or two earlier treatments could be judged, and more than half got the pair as their third treatment.¹ Tumors shrank enough to count as a response in 82% of them. At the cutoff only 11 of the 18 responses were confirmed, and Tango says the other 7 were confirmed afterwards.² Counting only responses confirmed at the cutoff, the rate was 50%. At nine months 88% had not seen their cancer grow, though the 95% range around that estimate runs from 60% to 97%. The median time before growth has not been reached, and no second-line patient has progressed.³

At the lower dose, the one picked for the Phase 3, 40% of pancreatic patients had serious (Grade 3) side effects tied to treatment. A higher vopimetostat dose was not well tolerated.¹ A second pairing, with Revolution's zoldonrasib, produced a 54% response rate in 35 patients.² Tango's chief executive says the results beat any published pancreatic dataset, even in front-line use. Tango's own slides warn that no head-to-head trial has been run and that such comparisons need caution.³

After talks with the Food and Drug Administration, Tango plans a global Phase 3 trial in front-line patients, meaning those getting their first treatment for advanced disease.¹ It would enroll 484 patients and split them evenly between vopimetostat plus daraxonrasib and standard chemotherapy. The two main goals are response rate and time before the cancer grows, with overall survival as a key secondary goal.² Tango expects to start in the first half of 2027 and plans to ask regulators about approval in second-line patients, which is not agreed. It counts about 20,000 American front-line patients a year with the MTAP loss.³

The weak link is supply. Tango says it is pursuing multiple pathways to get daraxonrasib for the trial, and its risk list names the chance it cannot secure enough for the Phase 3.¹ The existing deal gives free supply for trials that include vopimetostat, but whether that stretches to a 484-patient Phase 3 is the open question.² Tango also buys the active ingredient for all its clinical drugs from one WuXi AppTec affiliate.³

Money is not the near-term problem. On June 30, 2026 Tango held $345.6 million of cash and $668.4 million of marketable securities, $1.01 billion in all.¹ Total liabilities were only $49.3 million, most of it lease obligations; the leases call for $42.0 million of future payments, $5.9 million of it within a year.² With so little owed and no earnings, debt ratios such as debt to earnings do not apply.³ Operations used $83.2 million of cash in the first half, about $41.6 million a quarter. At that pace the cash would last about six years, but Tango plans to raise research spending substantially and a 484-patient trial is costly.⁴

Tango's own cash promises vary by document. Its August prospectus said cash would fund operations for at least the next 12 months, where its November 2025 prospectus said into 2028.¹ Its quarterly release said the cash carries it through pancreatic development and launch preparation, without a date. Its slides add that it may use cash faster than planned.²

Reported losses run ahead of cash burn. The six-month net loss was $100.9 million, while operations used $83.2 million of cash, and stock pay, a non-cash cost, was $27.7 million in the half.¹ In the second quarter, overhead stock pay rose to $12.1 million, mainly because older awards were changed. Interest on the cash added $3.7 million in the quarter.² Any severance cost from the cut has not been sized, so the next quarter's loss may carry a charge that does not repeat.

Owners face more dilution, not less. Tango had 168,610,367 shares out on August 4, 2026.¹ Adding 21.8 million options with an average strike of $8.84, 1.9 million restricted stock units and 5.06 million pre-funded warrants that cost $0.001 to exercise, the June 30 count rises to about 197 million.² The stock program allows up to $400 million of sales, including $35.6 million left over from an older program that had sold $64.4 million. At $23.97 a share, $400 million would mean about 16.7 million new shares, about 10% more stock, and the agent, Leerink Partners, earns up to 3%.³

Tango can sell large amounts of that stock at any time.¹ No convertible preferred stock is outstanding, and total liabilities were $49.3 million, so little stands ahead of common holders.² At mid-year, Farallon Capital Management reported owning 9.8% of the stock, counting 3,993,187 pre-funded warrants on top of its 12,277,000 shares.³ Goldman Sachs reported a 6.0% stake at mid-year.⁴ TCG Crossover Fund II reported 10.1 million shares, which it put at 7.0% of a pre-offering share count; that is about 6% of today's count.⁵ Adam Crystal, the president of research and development, exercised 27,000 options at $5.20 in early October and sold all 27,000 shares at $24.45 to $25.32; his trading plans allow up to 355,506 shares through October 2026 and 210,000 more through October 2027.⁶

TNGX moved down 14.2% since the filing, from its $27.94 close on October 22, 2026 to $23.97 at 13:52 ET on October 23, 2026. The S&P 500 fund (SPY) moved down 0.4% over the same span, and the SPDR biotech fund (XBI) fell about 1.3%.¹ Part of the drop undid a run-up: the stock had climbed 26.7% from its $22.05 close on October 16, 2026 into the release. It now sits about 20% below the $30.00 offering price and above the $21.76 low close in our price file, which starts in mid-September.² One release carried the data, the cut and the delays, so the move cannot be pinned on any one of them. At about $4.04 billion, the market values Tango's drugs at roughly $3.03 billion above its cash.³

The bull case: an 82% response rate in previously treated pancreatic cancer, no progression among second-line patients and an 88% nine-month rate suggest the responses last.¹ The Phase 3 was shaped after talks with the Food and Drug Administration and uses response rate as one of two main goals, an earlier measure than survival. Tango has $1.01 billion to pay for it, and the cut sends more of that money to its most advanced drug.²

The bear case, strongest point first. The Phase 3 depends on a drug Tango does not own, and supply is not yet secured.¹ The data rest on 22 patients with no comparison group, the headline rate slipped from 92% to 82% as patients were added, and only half had a confirmed response at the cutoff.² Among the 25 pancreatic patients at dose level 1, the dose the slides say was selected for the Phase 3, the Grade 3 side-effect rate was 40%.³ Discovery is deprioritized, and up to $400 million of new stock can be sold into the market.⁴

Tango's own goals, which are plans and not promises: start the 484-patient Phase 3 and a study in pancreatic tumors without the MTAP loss in the first half of 2027, report the lung and TNG456 data in January 2027, and discuss a second-line approval with regulators.¹ Its slides say its cash is expected to support late-stage pancreatic work.²

The dated tests start with Tango's poster at the European cancer meeting on Sunday, October 25, 2026. The next quarterly report should show any charge from the cut and any new stock sold.¹ January 2027 brings the lung and TNG456 data, and the first half of 2027 should bring the Phase 3 start, which needs daraxonrasib supply settled first.² Our view that the stock stays below $30.00 would be wrong if Tango announces a supply deal for the Phase 3 or if new data lift the whole PRMT5 story.³

The 8-K sizes the cut only as about 14% of the workforce. It gives no charge, severance cost or yearly savings, so the cut cannot yet be measured against the loss.

No headcount is given for the cut or for today's staff; the last count was 137 full-time employees at the end of 2025.

Tango gives no reason for moving the lung cancer and TNG456 data to January 2027.

Tango says it is pursuing multiple pathways to get daraxonrasib but names no deal, supplier terms or price.

The filings do not say how much stock, if any, Tango has sold under the $400 million program since it opened.

Tango gives no budget for the 484-patient trial and no new runway date after the cut.